Q-omics provides the consensus-scored GSTA4 profile across patient tissues and cancer cell-line models. GSTA4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GSTA4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, GSTA4 protein abundance shows 21,790 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where GSTA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTA4 survival associations across molecular data types. GSTA4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTA4 RNA expression–survival associations across cancer types. High GSTA4 expression shows unfavorable associations in BRCA, ACC and KIRP, but favorable associations in KIRC, LUSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GSTA4 RNA expression.
This table summarizes GSTA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GSTA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTA4 shows lower tumor expression in KICH, LUAD, THCA, KIRP and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher GSTA4 RNA expression in normal versus tumor tissue (log2 FC = −2.822, t-test p < 0.001).
This table shows molecular features associated with GSTA4 in patient tissues and cancer cell lines. In patient samples, GSTA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GSTA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
